| 1. |
Screening Trial to Study Eligibility of Patients to Participate in Head
and Neck Surgery Clinical Trials
|
| 2. |
Combination Chemotherapy, Surgery, and Radiation Therapy in Treating
Patients With Non-Small Cell Lung Cancer
|
| 3. |
Peripheral Stem Cell Transplant in Treating Older Patients With Acute
Myeloid Leukemia
|
| 4. |
Combination Chemotherapy With or Without Whole-Body
Hyperthermia in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or
Peritoneal Cancer
|
| 5. |
Biological Therapy in Treating Patients With Metastatic Melanoma
|
| 6. |
Vaccine Therapy in Treating Patients With Stage II or Stage III
Melanoma That Has Been Surgically Removed
|
| 7. |
Screening Individuals and Families at High Risk for Hematologic
Cancers
|
| 8. |
Genetic Study of Patients With Acute Myeloid Leukemia, Acute
Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Multiple Myeloma
|
| 9. |
Study of Individuals and Families at High Risk for Breast or Ovarian
Cancer
|
| 10. |
Cisplatin Combined With Either Irinotecan or Etoposide in Treating Patients
With Extensive-Stage Small Cell Lung Cancer
|
| 11. |
Erlotinib and Irinotecan in Treating Patients With Advanced Solid
Tumors
|
| 12. |
Study of Individuals and Families at High Risk for Melanoma
|
| 13. |
Combination Chemotherapy Followed By Observation or Surgery in
Treating Patients With Stage II or Stage III Cancer of the Urothelium
|
| 14. |
Reduced-Intensity Regimen Before Donor Bone Marrow Transplant in
Treating Patients With Myelodysplastic Syndromes
|
| 15. |
EGb761 in Maintaining Mental Clarity in Women
Receiving Chemotherapy for Newly Diagnosed Breast Cancer
|
| 16. |
Combination Chemotherapy in Treating Patients With Advanced Solid
Tumors
|
| 17. |
Diagnostic Study of Tumor Characteristics in Patients With Ewing's Sarcoma
|
| 18. |
Epoetin beta in Treating Anemia in Patients With Cervical Cancer
|
| 19. |
Radiation Therapy in Preventing CNS Metastases in Patients With Non-Small
Cell Lung Cancer
|
| 20. |
Combination Chemotherapy in Treating Patients With Colon Cancer
|
| 21. |
Combination Chemotherapy in Treating Patients With Advanced Solid
Tumors
|
| 22. |
Sirolimus in Treating Patients With Glioblastoma Multiforme
|
| 23. |
Alemtuzumab Followed by Peripheral Stem Cell Transplantation in Treating
Patients With Advanced Mycosis Fungoides/Sezary Syndrome
|
| 24. |
Chemotherapy Before and After Surgery in Treating Children With
Wilm's Tumor
|
| 25. |
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon
Cancer That Has Not Responded to Vaccine Therapy
|
| 26. |
Combination Chemotherapy in Treating Women With Breast Cancer
|
| 27. |
Donor Stem Cell Transplant With or Without Chemotherapy in Treating
Children With Primary Myelodysplastic Syndrome
|
| 28. |
Radiolabeled Octreotide in Treating Children With Advanced or Refractory
Solid Tumors
|
| 29. |
Flavopiridol Plus Radiation Therapy Followed By Gemcitabine in Treating
Patients With Locally Advanced, Unresectable Pancreatic Cancer
|
| 30. |
Neoadjuvant Chemotherapy With or Without Second-Look Surgery Followed by Radiation Therapy With or Without Peripheral Stem Cell Transplantation in Treating Patients With Intracranial Germ Cell Tumors
|
| 31. |
Screening Study of Surgery and CA 125 Levels in Participants at Increased
Genetic Risk of Ovarian Cancer
|
| 32. |
Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With
Locally Advanced Breast Cancer
|
| 33. |
Chemotherapy Followed By Vaccine Therapy in Treating Patients With
Extensive-Stage Small Cell Lung Cancer
|
| 34. |
EF5 Compared With Other Methods of Detecting Oxygen Levels in
Tumor Cells of Patients With Head and Neck Cancer
|
| 35. |
Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients
With Mouth or Throat Cancer
|
| 36. |
Chemoembolization and Bevacizumab in Treating Patients With Liver Cancer
That Cannot Be Removed With Surgery
|
| 37. |
Paclitaxel and Carboplatin in Treating Patients With Metastatic
Prostate Cancer That Has Not Responded to Hormone Therapy
|
| 38. |
Zoledronate in Preventing Bone Loss in Premenopausal Women Receiving
Chemotherapy After Surgery For Early Stage Breast Cancer
|
| 39. |
Combining Chemotherapy, Tacrolimus, Mycophenolate Mofetil, and
Radiation Therapy with Donor Bone Marrow Transplant in Treating Patients with
Hematologic Cancer
|
| 40. |
Combination Chemotherapy With or Without Monoclonal Antibody Therapy
Followed by Stem Cell Transplant in Treating Patients With Acute Myeloid
Leukemia
|
| 41. |
PEG-Interferon Alfa-2b in Treating Patients With Stage IV
Melanoma
|
| 42. |
Comparison of Two Combination Chemotherapy Regimens in Treating
Patients With Stage III or Stage IV Hodgkin's Lymphoma
|
| 43. |
Gemcitabine Combined With Mistletoe in Treating Patients With Advanced
Solid Tumors
|
| 44. |
Cancer Risk in Individuals Who Have a Xeroderma
Pigmentosum Gene Alteration Compared With Those Who Don't
|
| 45. |
Donor Peripheral Stem Cell Transplant in Treating Patients With
Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Myeloproliferative
Disorder
|
| 46. |
Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia
|
| 47. |
Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer
|
| 48. |
Thalidomide and Prednisone After Autologous Stem Cell Transplantation in
Treating Patients With Multiple Myeloma
|
| 49. |
Combination Chemotherapy and Radiation Therapy With or Without Surgery In Treating Patients With Stage II or Stage III Bladder Cancer
|
| 50. |
High-Dose Radiation Therapy Plus Chemotherapy in Treating Patients With Advanced Nose or Throat Cancer
|
| 51. |
Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer
|
| 52. |
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
|
| 53. |
Biological Therapy in Treating Patients With Advanced Acute or Chronic Myeloid Leukemia or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation
|
| 54. |
Bevacizumab, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II or Stage III Rectal Cancer
|
| 55. |
Adoptive Immunotherapy and Interleukin-2 in Treating Patients With Recurrent Myeloid Leukemias After Undergoing Allogeneic Stem Cell Transplantation
|
| 56. |
PEG-Interferon alfa-2b and Thalidomide in Treating Patients With Recurrent High-Grade Gliomas
|
| 57. |
Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer
|
| 58. |
FR901228 in Treating Patients With Refractory Thyroid Cancer or Other Advanced Cancer
|
| 59. |
Amifostine and Melphalan in Treating Patients With Primary Systemic Amyloidosis Who Are Undergoing Peripheral Stem Cell Transplantation
|
| 60. |
Chemotherapy and Radiation Therapy After Surgery in Treating Patients With Stomach or Esophageal Cancer
|
| 61. |
Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Non-Hodgkin's Lymphoma
|
| 62. |
Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas
|
| 63. |
Monoclonal Antibody Therapy in Treating Patients with Refractory Lymphoma
|
| 64. |
Combination Chemotherapy With or Without Rituximab in Treating Patients With Mantle Cell Lymphoma
|
| 65. |
Topotecan in Treating Patients With Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
|
| 66. |
Vaccine Therapy Before and After Dose-Intensive Induction Chemotherapy Plus Immune-Depleting Chemotherapy in Treating Patients With Metastatic Breast Cancer
|
| 67. |
Combination Chemotherapy and Thalidomide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
|
| 68. |
Combination Chemotherapy Followed By Radiation Therapy in Treating Patients With Aggressive Non-Hodgkin's Lymphoma
|
| 69. |
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
|
| 70. |
Buspirone in Reducing Shortness of Breath in Patients With Cancer
|
| 71. |
Radiation Therapy Plus Combination Chemotherapy in Treating Children With Medulloblastoma
|
| 72. |
Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Aplastic Anemia
|
| 73. |
Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
|
| 74. |
Suramin and Paclitaxel in Treating Women With Stage IIIB or Stage IV Breast Cancer
|
| 75. |
Study of Decision Making in Patients Participating in Phase I Clinical Trials
|
| 76. |
Genetic Study of Cancer Risk and Gene Identification in Patients and Families With Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome
|
| 77. |
Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia
|
| 78. |
Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
|
| 79. |
Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
|
| 80. |
Stem Cell Transplantation in Treating Patients With Previously-Treated Multiple Myeloma
|
| 81. |
Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
|
| 82. |
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
|
| 83. |
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
|
| 84. |
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
|
| 85. |
Combination Chemotherapy in Treating Women With Stage I Breast Cancer
|
| 86. |
Bevacizumab in Treating Patients With Unresectable Nonmetastatic Liver Cancer
|
| 87. |
Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors
|
| 88. |
Hormone Therapy With or Without Docetaxel And Estramustine in Treating Patients With Prostate Cancer That is Locally Advanced or At High Risk of Relapse
|
| 89. |
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
|
| 90. |
Genetic Study of Familial Factors in Patients With Colon Cancer
|
| 91. |
Collection and Storage of Blood and Tissue Samples From Patients Who Are Undergoing Surgery For Lung Cancer
|
| 92. |
Combination Chemotherapy Plus Erlotinib in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
|
| 93. |
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes
|
| 94. |
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
|
| 95. |
Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin
|
| 96. |
Celecoxib in Preventing Lung Cancer in Former Heavy Smokers
|
| 97. |
Bexarotene in Preventing Breast Cancer in Women at Genetic Risk
|
| 98. |
Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia
|
| 99. |
Combination Chemotherapy Plus Cetuximab in Treating Patients With Liver Metastases from Colorectal Cancer
|
| 100. |
Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides
|
| 101. |
Allogeneic Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer
|
| 102. |
Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma
|
| 103. |
Surgery Followed By Chemotherapy With or Without Intraperitoneal Chemotherapy in Treating Patients With Peritoneal Carcinomatosis From Gastrointestinal Cancer
|
| 104. |
Genetic Study of Cancer Risk and Gene Identification in Patients With Inherited Bone Marrow Disorders and Their Families
|
| 105. |
Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Extensive-Stage Small Cell Lung Cancer
|
| 106. |
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
|
| 107. |
Anastrozole and Gefitinib Compared With Fulvestrant and Gefitinib in Treating Postmenopausal Women With Recurrent or Metastatic Breast Cancer
|
| 108. |
Reduced-Intensity Regimen Before Allogeneic Bone Marrow Transplantation in Treating Patients With Relapsed Non-Hodgkin's or Hodgkin's Lymphoma
|
| 109. |
Alemtuzumab in Treating Patients With Relapsed or Refractory Advanced Mycosis Fungoides or Sézary Syndrome
|
| 110. |
BMS-247550 in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
|
| 111. |
Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer
|
| 112. |
Bevacizumab in Treating Patients With Kaposi's Sarcoma
|
| 113. |
Zoledronate in Preventing Bone Loss Caused By Long-Term Androgen Deprivation Therapy in Patients With Stage III or Stage IV Prostate Cancer
|
| 114. |
Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer
|
| 115. |
Flavopiridol, Fludarabine, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
|
| 116. |
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
|
| 117. |
Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors
|
| 118. |
Genistein in Treating Patients With Localized Prostate Cancer Who Are Planning to Undergo Radical Prostatectomy
|
| 119. |
Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer
|
| 120. |
Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation
|
| 121. |
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
|
| 122. |
Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma
|
| 123. |
Rituximab and Combination Chemotherapy Combined With Yttrium Y 90 Ibritumomab Tiuxetan in Treating Older Patients With Previously Untreated B-Cell Lymphoma
|
| 124. |
Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
|
| 125. |
Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma
|
| 126. |
Epirubicin and Thalidomide in Treating Patients With Liver Cancer
|
| 127. |
Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
|
| 128. |
Anal Sphincter Prosthesis in Treating Patients Who Are Undergoing Surgery for Anal or Rectal Cancer
|
| 129. |
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
|
| 130. |
Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma
|
| 131. |
Morinda Citrifolia in Treating Patients With Advanced Cancer
|
| 132. |
Acupuncture in Improving Quality of LIfe in Patients With Metastatic Colorectal Cancer
|
| 133. |
Combination Chemotherapy, Monoclonal Antibody, and Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma
|
| 134. |
Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
|
| 135. |
High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors
|
| 136. |
Adjuvant Radiation Therapy in Treating Patients With Resected Desmoplastic Melanoma
|
| 137. |
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia
|
| 138. |
Monoclonal Antibody Therapy After Allogeneic Stem Cell Transplantation in Treating Patients With Persistent or Progressive Cancer
|
| 139. |
Low-Dose Chemotherapy and Radiation Therapy Before Donor Stem Cell Transplant in Treating Patients With Refractory Chronic Lymphocytic Leukemia
|
| 140. |
Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors
|
| 141. |
Carboplatin and Etoposide With or Without Thalidomide in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer
|
| 142. |
Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach (Group Two Closed to Accrual as of 9/19/2006)
|
| 143. |
Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have von Hippel-Lindau Syndrome or Are at Risk for von Hippel-Lindau Syndrome
|
| 144. |
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
|
| 145. |
Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma
|
| 146. |
Interferon alfa, Isotretinoin, and Paclitaxel in Treating Patients With Recurrent Small Cell Lung Cancer
|
| 147. |
Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma
|
| 148. |
Interleukin-7 in Treating Patients With Refractory Solid Tumors
|
| 149. |
FR901228 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
| 150. |
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
|
| 151. |
Diagnostic and Genetic Study to Identify Pancreatic Lesions in Patients With Von Hippel-Lindau Syndrome
|
| 152. |
Paclitaxel and Carboplatin With or Without Celecoxib Before Surgery in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer
|
| 153. |
Moxifloxacin Compared With Ciprofloxacin/Amoxicillin in Treating Fever and Neutropenia in Patients With Cancer
|
| 154. |
Boronophenylalanine-Fructose Complex (BPA-F) and/or Sodium Borocaptate (BSH) Followed By Surgery in Treating Patients With Thyroid Cancer, Head and Neck Cancer, or Liver Metastases
|
| 155. |
Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction
|
| 156. |
Assessing Women's Attitudes About the Risk of Infertility Related to Adjuvant Therapy for Early Breast Cancer
|
| 157. |
Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors
|
| 158. |
Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer
|
| 159. |
Esophagectomy in Treating Patients With High-Grade Dysplasia of the Esophagus or Stage I, Stage II, or Stage III Esophageal Cancer
|
| 160. |
Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
|
| 161. |
Collecting and Counting the Number of Endothelial Cells in the Circulating Blood of Patients with Cancer, Patients Having Surgery, and Healthy Volunteers
|
| 162. |
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
|
| 163. |
Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma
|
| 164. |
Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix
|
| 165. |
Gene Therapy in Preventing Cancer in Patients With Premalignant Carcinoma of the Oral Cavity or Pharynx
|
| 166. |
Monoclonal Antibody and Sargramostim in Treating Patients With Metastatic Prostate Cancer
|
| 167. |
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
|
| 168. |
Alemtuzumab in Treating Patients With HTLV-1 Associated Adult T-Cell Leukemia/Lymphoma
|
| 169. |
Gemcitabine and Radiation Therapy Compared With Gemcitabine Alone in Treating Patients Who Have Undergone Surgery for Pancreatic Cancer
|
| 170. |
Ginger in Treating Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer
|
| 171. |
Fruit and Vegetable Extracts in Treating Patients With Stage I, Stage II, Stage III, Stage IVA, or Stage IVB Head and Neck Cancer
|
| 172. |
High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
|
| 173. |
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
|
| 174. |
Inhaled Sargramostim in Treating Patients With First Pulmonary (Lung) Recurrence of Osteosarcoma
|
| 175. |
Captopril in Treating Patients With Non-Small Cell Lung Cancer or Limited-Stage Small Cell Lung Cancer That Has Been Previously Treated With Radiation Therapy With or Without Chemotherapy
|
| 176. |
Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer
|
| 177. |
Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia
|
| 178. |
Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer
|
| 179. |
Radiation Therapy to the Abdomen Plus Docetaxel in Treating Patients With Recurrent or Persistent Advanced Ovarian, Peritoneal, or Fallopian Tube Cancer
|
| 180. |
Cyclophosphamide, Rituximab, and Either Prednisone or Methylprednisolone in Treating Patients With Lymphoproliferative Disease After Solid Organ Transplantation
|
| 181. |
Exemestane or Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Primary Breast Cancer
|
| 182. |
Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
|
| 183. |
Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer
|
| 184. |
Serum Protein Patterns in Participants With Mycosis Fungoides/Cutaneous T-Cell Lymphoma, Psoriasis, or Normal Skin
|
| 185. |
Bevacizumab With or Without Docetaxel in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
|
| 186. |
Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
|
| 187. |
Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer
|
| 188. |
Cyclosporine, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
|
| 189. |
Suppression of Ovarian Function and Either Tamoxifen or Exemestane With or Without Chemotherapy in Treating Premenopausal Women With Resected Breast Cancer
|
| 190. |
Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer
|
| 191. |
Sirolimus in Treating Young Patients With Relapsed or Refractory Acute Leukemia or Non-Hodgkin's Lymphoma
|
| 192. |
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
| 193. |
Chemotherapy Decisions and Outcomes in Older Women With Newly Diagnosed Breast Cancer
|
| 194. |
Docetaxel and Carboplatin With or Without Trastuzumab Before Surgery in Treating Women With Locally Advanced Breast Cancer
|
| 195. |
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma (Kidney Cancer)
|
| 196. |
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva
|
| 197. |
Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor
|
| 198. |
Collecting and Storing Tissue Samples Taken From Patients With Endometrial Cancer During Surgery to Determine the Stage of the Cancer
|
| 199. |
Vaccine Therapy in Treating Patients With Malignant Glioma
|
| 200. |
Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer
|
| 201. |
Chemotherapy, Interferon alfa, and Radiation Therapy in Treating Patients Who Have Undergone Surgery For Pancreatic Cancer
|
| 202. |
Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer
|
| 203. |
Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and Unresectable Cancer of the Central Nervous System
|
| 204. |
Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma
|
| 205. |
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Allogeneic Transplantation
|
| 206. |
Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer
|
| 207. |
Lonafarnib, Trastuzumab, and Paclitaxel in Treating Patients With HER2/neu-Overexpressing Stage IIIB, Stage IIIC, or Stage IV Breast Cancer
|
| 208. |
Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
|
| 209. |
Low-Dose Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Allogeneic Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Chronic Myelogenous Leukemia
|
| 210. |
J-Pouch Coloanal Anastomosis Compared With Side-to-End Coloanal Anastomosis After Radiation Therapy and Surgery to Remove the Rectum in Treating Patients With Rectal Adenocarcinoma
|
| 211. |
Collecting and Storing Blood and Bone Marrow Samples From Patients With Myeloma, Waldenstrom's Macroglobulinemia, Amyloidosis, or Monoclonal Gammopathy of Undetermined Significance
|
| 212. |
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
|
| 213. |
Ecteinascidin 743 in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors
|
| 214. |
Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Myeloid Leukemia in First Complete Remission
|
| 215. |
Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors
|
| 216. |
Oxandrolone Compared With Megestrol in Preventing Weight Loss in Patients Receiving Chemotherapy for Cancer
|
| 217. |
Leucovorin and Fluorouracil With or Without Oxaliplatin Compared to Capecitabine With or Without Oxaliplatin in Treating Patients With Metastatic Colorectal Cancer
|
| 218. |
Autologous or Donor Cytotoxic T-Lymphocytes in Treating Patients With Relapsed Epstein-Barr Virus-Associated Hodgkin's Lymphoma or Non-Hodgkin's Lymphoma
|
| 219. |
Flavopiridol in Treating Patients With Metastatic or Unresectable Refractory Solid Tumors or Hematologic Malignancies
|
| 220. |
Coenzyme Q10 in Relieving Treatment-Related Fatigue in Women With Breast Cancer
|
| 221. |
Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer
|
| 222. |
Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell Lymphoma
|
| 223. |
Gemcitabine and Vinorelbine in Treating Young Patients With Recurrent or Refractory Hodgkin's Lymphoma
|
| 224. |
Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer
|
| 225. |
Breast Duct Lavage, Breast Duct Endoscopy, and Gene Expression Profiling in Women With Breast Cancer Compared With Healthy Women Who Are and Are Not at High Risk for Breast Cancer
|
| 226. |
Imatinib Mesylate or Dasatinib in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
|
| 227. |
Proton Nuclear Magnetic Resonance Spectroscopic Imaging Compared With Fludeoxyglucose F 18 Positron Emission Tomography Scanning in Determining Biologic or Metabolic Tumor Activity in Young Patients With Brain Tumors
|
| 228. |
GTI-2040 and High-Dose Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia
|
| 229. |
Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
|
| 230. |
Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma
|
| 231. |
Interleukin-12 Gene in Treating Patients With Liver Metastases Secondary to Colorectal Cancer
|
| 232. |
Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
|
| 233. |
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
|
| 234. |
CCI-779 in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
|
| 235. |
Tariquidar and Docetaxel in Treating Patients With Recurrent or Metastatic Lung, Ovarian, Cervical Cancer, or Kidney Cancer
|
| 236. |
Neoadjuvant Capecitabine and Radiation Therapy With or Without TNFerade Followed By Surgical Resection in Treating Patients With Stage II, Stage III, or Locally Recurrent Rectal Cancer
|
| 237. |
Alemtuzumab Combined With Etoposide, Vincristine, Doxorubicin, Cyclophosphamide, and Prednisone in Treating Patients Who Have Not Received Chemotherapy For T-Cell or NK-Cell Lymphoma
|
| 238. |
Surgery and/or Chemotherapy in Treating Children With Infantile, Congenital, or Childhood Fibrosarcoma
|
| 239. |
Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases
|
| 240. |
Neoadjuvant and Adjuvant Pamidronate With Induction and Maintenance Chemotherapy in Treating Patients With Osteosarcoma
|
| 241. |
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma
|
| 242. |
Systemic Vincristine, Carboplatin, and Etoposide, Subtenon Carboplatin, and Local Ophthalmic Therapy in Treating Children With Intraocular Retinoblastoma
|
| 243. |
Gemcitabine and Flavopiridol in Treating Patients With Solid Tumors
|
| 244. |
Rituximab in Treating Patients With Refractory or Relapsed Primary CNS Lymphoma
|
| 245. |
Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
|
| 246. |
Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
|
| 247. |
Whole-Body MRI and Conventional Imaging in Detecting Distant Metastases in Young Patients With Solid Tumors or Lymphoma
|
| 248. |
Gemcitabine, Carboplatin, and Dexamethasone With or Without Rituximab in Treating Patients With Relapsed or Primary Refractory Lymphoma
|
| 249. |
Iodine I 131 Tositumomab, Etoposide, and Cyclophosphamide Followed by Autologous Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
| 250. |
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
|
| 251. |
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
|
| 252. |
Tariquidar, Mitotane, Doxorubicin, Vincristine, and Etoposide Plus Surgery in Treating Patients With Recurrent, Metastatic, or Primary Unresectable Adrenocortical Cancer
|
| 253. |
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
|
| 254. |
BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia
|
| 255. |
Infliximab in Treating Patients With Myelodysplastic Syndrome
|
| 256. |
Liposomal Doxorubicin in Treating Patients With Stage IIB, Stage IVA, or Stage IVB Recurrent or Refractory Mycosis Fungoides
|
| 257. |
Adjuvant Chemotherapy in Treating Women Who Have Undergone Resection for Relapsed Breast Cancer
|
| 258. |
Rituximab, Carboplatin, Cyclophosphamide, and Etoposide or Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Sodium Thiosulfate and Cytarabine in Treating Patients With Refractory or Recurrent Primary CNS Lymphoma
|
| 259. |
Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
|
| 260. |
Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma
|
| 261. |
Induction Therapy Using Cisplatin, Etoposide, and Radiation Therapy Followed By Consolidation Therapy Using Gemcitabine With or Without Docetaxel in Treating Patients With Unresectable Stage IIIB Non-Small Cell Lung Cancer
|
| 262. |
BB-10901 in Treating Patients With Recurrent or Refractory Lung Cancer, Metastatic Carcinoid Tumor, or Other Solid Tumors
|
| 263. |
Allogeneic Peripheral Stem Cell Transplant After Antithymocyte Globulin, High-Dose Melphalan, and Fludarabine in Treating Women With Metastatic Adenocarcinoma of the Breast
|
| 264. |
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
|
| 265. |
Irinotecan, Oxaliplatin, and Capecitabine in Treating Patients With Unresectable Solid Tumors
|
| 266. |
Siplizumab in Treating Patients With Lymphoproliferative Disorder
|
| 267. |
Carboplatin, Cyclophosphamide, and Etoposide or Etoposide Phosphate With or Without Sodium Thiosulfate in Treating Patients With High-Grade Glioma
|
| 268. |
Rituximab in Treating Patients With Low Tumor Burden Indolent Non-Hodgkin's Lymphoma
|
| 269. |
Total-Body Irradiation With Or Without Fludarabine Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
|
| 270. |
3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Biliary Duct or Gallbladder Cancer
|
| 271. |
Vincristine, Dactinomycin, and Cyclophosphamide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Low-Risk Rhabdomyosarcoma
|
| 272. |
Second Autologous Stem Cell Transplant in Treating Patients With Persistent or Recurrent Primary Systemic (AL) Amyloidosis
|
| 273. |
Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma
|
| 274. |
Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma
|
| 275. |
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
|
| 276. |
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
|
| 277. |
Anastrozole With or Without Fulvestrant as First-Line Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer
|
| 278. |
Valproic Acid in Treating Patients With Kaposi’s Sarcoma
|
| 279. |
Vaccine Therapy in Treating Patients With Advanced Refractory or Recurrent Non-Small Cell Lung Cancer
|
| 280. |
Fluconazole Compared With Voriconazole in Preventing Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Transplantation
|
| 281. |
Filgrastim-Mobilized Peripheral Stem Cell Transplantation Compared With Bone Marrow Transplantation From Unrelated Donors in Treating Patients With Hematologic Malignancies
|
| 282. |
Tandem Autologous Stem Cell Transplantation With or Without Maintenance Therapy After the Second Transplantation Compared With Autologous Stem Cell Transplantation Followed By Matched Sibling Allogeneic Stem Cell Transplantation in Patients With Stage II or Stage III Multiple Myeloma
|
| 283. |
Valeriana Officinalis (Valerian) for Improving Sleep in Patients With Cancer Receiving Adjuvant Therapy
|
| 284. |
Hyperbaric Oxygen Therapy Compared With Standard Therapy in Treating Chronic Arm Lymphedema in Women Who Have Undergone Radiation Therapy for Early Breast Cancer
|
| 285. |
Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer
|
| 286. |
Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome
|
| 287. |
Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma
|
| 288. |
Adjuvant Radiation Therapy Compared With Observation After Surgery in Treating Women With Estrogen Receptor Positive or Progesterone Receptor Positive Ductal Carcinoma In Situ of the Breast Who Are Receiving Tamoxifen or Anastrozole
|
| 289. |
Carboplatin, Vincristine, and Temozolomide in Treating Children With Progressive and/or Symptomatic Low-Grade Glioma
|
| 290. |
ABI-007 in Treating Patients With Chemotherapy-Naïve Stage IV Non-Small Cell Lung Cancer
|
| 291. |
Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma
|
| 292. |
Proteomic Profiling in Diagnosing Non-Small Cell Lung Cancer in Patients Who are Undergoing Lung Resection for Suspicious Stage I Lung Lesions
|
| 293. |
Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer
|
| 294. |
Intensive Neoadjuvant Chemotherapy in Treating Young Patients Undergoing Surgical Resection for High-Risk Hepatoblastoma
|
| 295. |
Sirolimus in Preventing Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
|
| 296. |
BL22 Immunotoxin In Treating Young Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma
|
| 297. |
Tipifarnib and Radiation Therapy in Treating Patients With Unresectable Locally Advanced Pancreatic Cancer
|
| 298. |
Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
|
| 299. |
Selenium in Treating Patients With Adenomatous Colorectal Polyps
|
| 300. |
Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer
|
| 301. |
Pirfenidone in Treating Young Patients With Neurofibromatosis Type I and Recurrent or Progressive Plexiform Neurofibromas
|
| 302. |
Comparison of Two Salvage Chemotherapy Regimens Before Autologous Stem Cell Transplantation With or Without Maintenance Rituximab in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
|
| 303. |
GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
|
| 304. |
Zoledronate in Preventing Skeletal (Bone)-Related Events in Patients Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases
|
| 305. |
3-AP and Doxorubicin In Treating Patients With Metastatic or Refractory Solid Tumors
|
| 306. |
Doxorubicin With or Without Chemoembolization in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)
|
| 307. |
Adjuvant Erlotinib After Completing Chemoradiotherapy in Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
|
| 308. |
Cisplatin or Carboplatin Combined With Gemcitabine in Treating Patients With Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor
|
| 309. |
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
|
| 310. |
Vinblastine, Cyclophosphamide, Procarbazine, Prednisolone, Etoposide, Mitoxantrone, and Bleomycin in Treating Older Patients With Hodgkin's Lymphoma
|
| 311. |
Irinotecan and Docetaxel in Treating Patients With Refractory Metastatic Breast Cancer
|
| 312. |
Oblimersen in Treating Patients With Metastatic or Recurrent Merkel Cell Carcinoma
|
| 313. |
Vaccine Plus Montanide ISA-51 and Sargramostim in Treating Patients With Stage IV Breast Cancer
|
| 314. |
Docetaxel and Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer
|
| 315. |
Vaccine Therapy With Either Neoadjuvant or Adjuvant Chemotherapy and Adjuvant Radiation Therapy in Treating Women With p53-Overexpressing Stage II or Stage III Breast Cancer
|
| 316. |
Monoclonal Antibody Therapy in Treating Patients With T-Cell Large Granular Lymphocyte Leukemia
|
| 317. |
CCI-779 in Treating Patients With Stage IIIB (With Pleural Effusion) or Stage IV Non-Small Cell Lung Cancer
|
| 318. |
Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin’s Lymphoma
|
| 319. |
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
|
| 320. |
Imatinib Mesylate in Treating Patients With Chronic Myelomonocytic Leukemia or Atypical Chronic Myeloid Leukemia
|
| 321. |
Deslorelin Combined With Low-Dose Add-Back Estradiol and Testosterone in Preventing Breast Cancer in Premenopausal Women Who Are at High Risk for This Disease
|
| 322. |
Flavopiridol, Gemcitabine, and Irinotecan in Treating Patients With Unresectable or Metastatic Solid Tumors
|
| 323. |
Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
|
| 324. |
Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer
|
| 325. |
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
| 326. |
Peritransplant Cyclosporine in Treating Patients With Hematologic Malignancies Undergoing T-Cell Depleted Allogeneic Stem Cell Transplant Followed By T-Cell Add-Back
|
| 327. |
Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma
|
| 328. |
FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
|
| 329. |
Bortezomib and Mitoxantrone in Treating Patients With Advanced or Metastatic Androgen-Independent Prostate Cancer
|
| 330. |
Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant
|
| 331. |
Short-Term Low-Dose Interferon alfa in Treating Patients With Cancer of the Urothelium
|
| 332. |
LMB-2 Immunotoxin in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
|
| 333. |
Sentinel Lymph Node Biopsy and Primary Tumor Gene Expression Profiling in Finding Axillary Lymph Node Metastases in Women Who Have Received Neoadjuvant Therapy for Stage II, Stage III, or Stage IV Breast Cancer
|
| 334. |
Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation
|
| 335. |
Mindfulness Relaxation Compared With Relaxing Music and Standard Symptom Management Education in Treating Patients Who Are Undergoing Chemotherapy For Newly Diagnosed Solid Tumors
|
| 336. |
Single-Fraction Radiation Therapy Compared With Multiple-Fraction Reirradiation Therapy in Treating Patients With Painful Bone Metastases
|
| 337. |
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
|
| 338. |
Temozolomide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
|
| 339. |
Flavopiridol, Oxaliplatin, Fluorouracil, and Leucovorin in Treating Patients With Advanced Solid Tumors
|
| 340. |
Nipple Aspiration, Ductal Lavage, and Duct Endoscopy in Screening Women at Moderate-to-High Risk of Developing Breast Cancer
|
| 341. |
Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia
|
| 342. |
Comparison of Two Induction Combination Chemotherapy Regimens Followed By High-Dose Consolidation Chemotherapy and Autologous Stem Cell Transplantation With or Without Rituximab as Maintenance Therapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
|
| 343. |
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
|
| 344. |
Study of Late-Occurring Complications in Childhood Cancer Survivors
|
| 345. |
hu14.18-Interleukin-2 Fusion Protein in Treating Young Patients With Recurrent or Refractory Neuroblastoma
|
| 346. |
Creatine in Treating Patients With Cancer-Associated Weight Loss
|
| 347. |
Celecoxib in Treating Patients With Cervical Intraepithelial Neoplasia
|
| 348. |
Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin Followed By High-Dose Cytarabine Followed By Either Gemtuzumab Ozogamicin or No Additional Therapy in Treating Patients With Previously Untreated De Novo Acute Myeloid Leukemia
|
| 349. |
Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
|
| 350. |
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
|
| 351. |
Adjuvant Cetuximab and Chemoradiotherapy Using Either Cisplatin or Docetaxel in Treating Patients With Resected Stage III or Stage IV Squamous Cell Carcinoma or Lymphoepithelioma of the Head and Neck
|
| 352. |
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
|
| 353. |
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma
|
| 354. |
Cisplatin, Metronomic Low-Dose Interferon alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer
|
| 355. |
Single-Dose Local Radiation Therapy Compared With Ibandronate in Treating Patients With Localized Metastatic Bone Pain
|
| 356. |
T-Cell-Depleted Allogeneic Stem Cell Transplantation Followed By Donor T Cells, Given After Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Metastatic Breast Cancer
|
| 357. |
Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer
|
| 358. |
Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate
|
| 359. |
Nipple Aspiration, Ductal Lavage, and Duct Endoscopy For Diagnostic Assessment in Women Undergoing Surgery for Breast Cancer
|
| 360. |
Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer
|
| 361. |
Iloprost in Preventing Lung Cancer in Patients at High Risk for This Disease
|
| 362. |
Gefitinib, Paclitaxel, and Radiation Therapy in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck
|
| 363. |
Fludeoxyglucose F18 Positron Emission Tomography Imaging In Assessing Patients Before and After Treatment for Locally Advanced Non-Small Cell Lung Cancer
|
| 364. |
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
|
| 365. |
Cisplatin and Flavopiridol in Treating Patients With Advanced Ovarian Epithelial Cancer or Primary Peritoneal Cancer
|
| 366. |
CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma
|
| 367. |
Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
|
| 368. |
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
|
| 369. |
Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer
|
| 370. |
Adjuvant Chemoradiotherapy Using Cisplatin and Docetaxel After Complete Resection in Treating Patients With Stage III or Stage IV Squamous Cell Carcinoma of the Head and Neck
|
| 371. |
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
| 372. |
Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line Chemotherapy
|
| 373. |
Computed Tomography (CT) Scans Using CT-On-Rails™ to Pinpoint the Location of the Tumor in Treating Patients With Prostate Cancer
|
| 374. |
Intensity-Modulated Radiation Therapy With or Without Decreased Radiation Dose to Erectile Tissue in Treating Patients With Stage II Prostate Cancer
|
| 375. |
Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Metastatic or Inoperable Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (Cancer)
|
| 376. |
Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans (DFSP) or Transformed Fibrosarcomatous DFSP
|
| 377. |
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma
|
| 378. |
Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall
|
| 379. |
Venlafaxine With or Without Zolpidem in Treating Hot Flashes and Associated Sleep Disorders in Women With Breast Cancer OR at High Risk for Developing Breast Cancer
|
| 380. |
Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma
|
| 381. |
FR901228 in Treating Patients With Unresectable Recurrent or Metastatic Squamous Cell Carcinoma (Cancer) of the Head and Neck
|
| 382. |
Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases
|
| 383. |
Calcitriol and Gefitinib With or Without Dexamethasone in Treating Patients With Advanced Solid Tumors
|
| 384. |
Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma
|
| 385. |
Neoadjuvant Cetuximab, Fluorouracil, and Pelvic Irradiation in Treating Patients With Locally Advanced or Locally Recurrent Rectal Cancer
|
| 386. |
Safingol and Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors
|
| 387. |
Intrathecal and Systemic Chemotherapy Combined With Radiation Therapy in Treating Young Patients With Newly Diagnosed Central Nervous System Atypical Teratoid/Rhabdoid Tumors
|
| 388. |
Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate
|
| 389. |
Irinotecan and 3-AP in Treating Patients With Metastatic or Unresectable Solid Tumors
|
| 390. |
Docetaxel and Carboplatin in Treating Patients With Recurrent Stage IVB Squamous Cell Carcinoma (Cancer) of the Cervix
|
| 391. |
Fluorescence and Reflectance Spectroscopy During Colposcopy in Detecting Cervical Intraepithelial Neoplasia and Dysplasia in Healthy Participants With a History of Normal Pap Smears
|
| 392. |
Computed Tomographic Colonography in Screening Healthy Participants for Colorectal Cancer
|
| 393. |
Letrozole With or Without GW572016 in Treating Postmenopausal Women With Stage IV Breast Cancer
|
| 394. |
Decitabine and Valproic Acid in Treating Patients With Non-Small Cell Lung Cancer
|
| 395. |
Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic Melanoma
|
| 396. |
Two Dose Levels of Capecitabine With Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer That Has Not Responded to Previous Anthracycline-Based Chemotherapy
|
| 397. |
Exemestane in Treating Postmenopausal Women at High Risk for Invasive Breast Cancer
|
| 398. |
LMB-2 Immunotoxin in Treating Patients With Cutaneous T-Cell Lymphoma
|
| 399. |
Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary CNS Germ Cell Tumor
|
| 400. |
Daunorubicin and Cytarabine With or Without Oblimersen in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
|
| 401. |
LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma
|
| 402. |
Neurobehavioral Complications in Children Who Were Previously Treated With Steroids and Intrathecal Therapy for Acute Lymphoblastic Leukemia
|
| 403. |
Radiation Therapy and Combination Chemotherapy Followed by Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
|
| 404. |
Vaccine Therapy and Radiation Therapy in Treating Patients With Carcinoembryonic Antigen-Positive Solid Tumors That Have Metastasized to the Liver
|
| 405. |
S-1 and Cisplatin Before Surgery in Treating Patients With Stage IV Gastric Cancer
|
| 406. |
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
| 407. |
Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer
|
| 408. |
Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131
|
| 409. |
Interferon beta in Treating Patients With Metastatic Cutaneous Melanoma or Ocular Melanoma
|
| 410. |
UCN-01 in Treating Patients With Relapsed or Refractory Lymphoma
|
| 411. |
Carboplatin Plus Docetaxel and Paclitaxel in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
|
| 412. |
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
|
| 413. |
Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder
|
| 414. |
Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma
|
| 415. |
Vaccine Therapy Combined With Interleukin-2 and Interferon alfa in Treating Patients With Metastatic Renal Cell Carcinoma (Kidney Cancer)
|
| 416. |
Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
|
| 417. |
Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metastatic Melanoma
|
| 418. |
Imatinib Mesylate in Treating Patients With Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans or Giant Cell Fibroblastoma
|
| 419. |
MRI in Finding Cancer in Patients With Confirmed or Suspected Prostate Cancer
|
| 420. |
FR901228 in Treating Patients With Recurrent High-Grade Gliomas
|
| 421. |
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
|
| 422. |
ABI-007, Carboplatin, and Trastuzumab in Treating Patients With HER2/neu-Overexpressing Metastatic Breast Cancer
|
| 423. |
Forodesine in Treating Patients With Recurrent or Refractory Advanced T-Cell Leukemia
|
| 424. |
Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer
|
| 425. |
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
|
| 426. |
Stereotactic Body Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer
|
| 427. |
Positron Emission Tomography Imaging Using Tariquidar and Technetium Tc 94m Sestamibi in Treating Patients With Cancer
|
| 428. |
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
|
| 429. |
Rasburicase and/or Allopurinol in Controlling High Levels of Uric Acid in the Blood and Tumor Lysis Syndrome in Patients With Leukemia, Lymphoma, or Solid Tumors
|
| 430. |
Rasburicase in Treating or Preventing High Levels of Uric Acid in the Blood and Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumors
|
| 431. |
Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum
|
| 432. |
Gefitinib, Trastuzumab, and Docetaxel in Treating Patients With Metastatic Breast Cancer
|
| 433. |
Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors
|
| 434. |
Oxaliplatin, Fluorouracil, Radiation Therapy, and Surgery in Treating Patients With Stage II or Stage III Cancer of the Esophagus or Gastroesophageal Junction
|
| 435. |
Beta-Glucan and Rituximab in Treating Young Patients With Relapsed or Progressive Lymphoma or Leukemia, or Lymphoproliferative Disorder Related to Donor Stem Cell Transplantation
|
| 436. |
Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer
|
| 437. |
Docetaxel and Erlotinib in Treating Older Patients With Prostate Cancer
|
| 438. |
Pemetrexed Disodium in Treating Patients With Persistent or Recurrent Endometrial Cancer
|
| 439. |
Topotecan in Treating Women With Persistent or Recurrent Cervical Cancer
|
| 440. |
Ixabepilone in Treating Patients With Metastatic Prostate Cancer
|
| 441. |
Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer
|
| 442. |
Rebeccamycin Analog in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
|
| 443. |
Intratumoral Transferrin-CRM107 Compared With Best Standard Chemotherapy in Treating Patients With Progressive and/or Recurrent Glioblastoma Multiforme
|
| 444. |
ABX-EGF in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Chemotherapy
|
| 445. |
Urine and Blood Protein Levels in Predicting One-Year Recurrence of Glioblastoma Multiforme in Patients Undergoing Radiation Therapy
|
| 446. |
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Stage III or Stage IV Melanoma
|
| 447. |
Triptorelin for Preserving Ovarian Function in Premenopausal Women Receiving Chemotherapy for Early-Stage Breast Cancer
|
| 448. |
Letrozole in Preventing Breast Cancer in Postmenopausal Women
|
| 449. |
Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
| 450. |
17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
|
| 451. |
Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Lymphoma
|
| 452. |
Docetaxel With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
|
| 453. |
Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
|
| 454. |
Erlotinib and Green Tea Extract (Polyphenon® E) in Preventing Cancer Recurrence in Former Smokers Who Have Undergone Surgery for Bladder Cancer
|
| 455. |
Celecoxib and Erlotinib in Treating Former Smokers With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
|
| 456. |
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
|
| 457. |
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer
|
| 458. |
Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer
|
| 459. |
MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma
|
| 460. |
Decitabine in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas
|
| 461. |
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced Unresectable or Metastatic Kidney Cancer
|
| 462. |
Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer
|
| 463. |
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
|
| 464. |
Immunosuppressive Treatment Regimens With or Without Mycophenolate Mofetil in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease
|
| 465. |
T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant
|
| 466. |
Radiation Therapy in Treating Patients Who Are Undergoing Surgery to Remove a Metastatic Brain Tumor
|
| 467. |
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
|
| 468. |
Biological Therapy in Treating Patients With Neuroblastoma That Has Not Responded to Previous Treatment
|
| 469. |
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
|
| 470. |
Motexafin Gadolinium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage II, Stage III, or Stage IV Relapsed or Refractory Non-Hodgkin's Lymphoma
|
| 471. |
Internal Radiation Therapy With or Without Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases
|
| 472. |
Sentinel Lymph Node Mapping in Detecting Cancer That Has Spread to Lymph Nodes in Patients With Non-Small Cell Lung Cancer
|
| 473. |
Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer
|
| 474. |
Alemtuzumab With or Without Methotrexate and Mercaptopurine in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia
|
| 475. |
17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors
|
| 476. |
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Von Hippel-Lindau Disease and Kidney Cancer
|
| 477. |
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Unresectable Colorectal Cancer That Has Metastasized to the Liver
|
| 478. |
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer
|
| 479. |
CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
|
| 480. |
APC8015F in Treating Patients With Progressive Metastatic Prostate Cancer and Disease-Related Pain
|
| 481. |
Pulmonary Rehabilitation Education With or Without Exercise Training in Improving Physical Function in Patients Who Are Undergoing Chemotherapy and Radiation Therapy for Locally Advanced Lung Cancer
|
| 482. |
Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma
|
| 483. |
Vaccine Therapy and Sargramostim in Treating Adults With Metastatic Cancer
|
| 484. |
Human Corticotropin-Releasing Factor in Controlling Symptoms Associated With Brain Swelling in Patients With Malignant Brain Tumors
|
| 485. |
Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer
|
| 486. |
Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery
|
| 487. |
Long-Term Effects of Treatment in Patients Previously Treated for Childhood Hodgkin's Lymphoma
|
| 488. |
Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Interleukin-2 in Treating Patients With Metastatic Melanoma
|
| 489. |
Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction
|
| 490. |
Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable or Metastatic Melanoma
|
| 491. |
Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
|
| 492. |
Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia
|
| 493. |
Hypericum Perforatum (St. John's wort) in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer
|
| 494. |
Vaccine Therapy in Treating Patients With Stage IIB, Stage III, or Stage IV Colorectal Cancer
|
| 495. |
ZD6474, Carboplatin, and Paclitaxel in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
|
| 496. |
Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer
|
| 497. |
Docetaxel, Bevacizumab, Thalidomide, and Prednisone in Treating Patients With Metastatic Androgen-Independent Prostate Cancer
|
| 498. |
Sorafenib in Treating Patients With Metastatic Prostate Cancer
|
| 499. |
Docetaxel, Radiation Therapy, and Hormone Therapy in Treating Patients With Locally Advanced Prostate Cancer
|
| 500. |
Heat Activated Liposomal Doxorubicin and Radiofrequency Ablation in Treating Patients With Primary or Metastatic Liver Tumors
|
| 501. |
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
|
| 502. |
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
|
| 503. |
Hyperthermia, Radiation Therapy, Surgery, and Optional Chemotherapy in Treating Patients With Soft Tissue Sarcoma of the Limbs
|
| 504. |
Vaccine Therapy With or Without Fludarabine in Treating Patients With Stage IV Kidney Cancer
|
| 505. |
Lapatinib in Treating Patients With Recurrent Glioblastoma Multiforme
|
| 506. |
Bevacizumab and Trastuzumab (Herceptin®) in Treating Women With Relapsed or Metastatic Breast Cancer
|
| 507. |
Cellular Adoptive Immunotherapy and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
|
| 508. |
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
|
| 509. |
Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma
|
| 510. |
Sorafenib in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Peritoneal Cancer
|
| 511. |
Celecoxib in Managing Pain, Weight Loss, and Weakness in Patients With Advanced Cancer
|
| 512. |
Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma
|
| 513. |
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
|
| 514. |
Docetaxel and Carboplatin With or Without Zoledronate in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer
|
| 515. |
Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
|
| 516. |
BMS-599626 in Treating Patients With Metastatic Solid Tumors
|
| 517. |
Fludarabine and Low-Dose Total-Body Irradiation Followed By Donor Stem Cell Transplantation and Mycophenolate Mofetil and Cyclosporine in Treating Patients With Fanconi’s Anemia
|
| 518. |
Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer
|
| 519. |
Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
|
| 520. |
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
|
| 521. |
Capecitabine, Vinorelbine, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
|
| 522. |
Combination Chemotherapy and Radiation Therapy in Treating Patients With Acute Lymphoblastic Leukemia That Has Relapsed in the CNS or Testes
|
| 523. |
Pemetrexed Disodium in Treating Patients With Recurrent or Persistent Low-Risk Gestational Trophoblastic Tumor After a Molar Pregnancy
|
| 524. |
Intralesional Resection in Treating Patients With Chondrosarcoma of the Bone
|
| 525. |
17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors
|
| 526. |
Pentostatin and Donor White Blood Cells in Preventing Graft Rejection in Cancer Patients Who Have Undergone Donor Stem Cell Transplantation
|
| 527. |
Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
|
| 528. |
Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia
|
| 529. |
Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer
|
| 530. |
17-N-Allylamino-17-Demethoxygeldanamycin (17-AAG) in Treating Women With Refractory Locally Advanced or Metastatic Breast Cancer
|
| 531. |
Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer
|
| 532. |
Monoclonal Antibody HuHMFG1 in Treating Women With Locally Advanced or Metastatic Breast Cancer
|
| 533. |
Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
|
| 534. |
Vaccine Therapy With or Without Cyclophosphamide and Doxorubicin in Women With Stage IV Breast Cancer
|
| 535. |
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
|
| 536. |
Valganciclovir in Treating Patients With Classic Non-HIV-Associated Kaposi's Sarcoma
|
| 537. |
Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer
|
| 538. |
Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer
|
| 539. |
Folate-Depleted Diet Compared With Folate-Supplemented Diet in Preventing Colorectal Cancer in Patients at High Risk for Colorectal Cancer
|
| 540. |
Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma
|
| 541. |
Lapatinib in Treating Young Patients With Recurrent or Refractory CNS Tumors
|
| 542. |
Radiation Therapy, Carboplatin, and Paclitaxel With or Without Amifostine in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer
|
| 543. |
Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma
|
| 544. |
Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
|
| 545. |
Vaccine Therapy, Interferon alfa, and Cyclophosphamide in Treating Women With Stage IV Breast Cancer
|
| 546. |
Pioglitazone in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia
|
| 547. |
Physical Activity in Preventing Breast Cancer in Women With a History of Breast Cancer or at High Risk for Breast Cancer Who are Not Physically Active
|
| 548. |
Antiretroviral Therapy With or Without Bortezomib or Combination Chemotherapy and Rituximab or Observation Only in Treating Patients With Castleman's Disease
|
| 549. |
Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas
|
| 550. |
Clinical Evaluations and Laboratory Studies in Patients With Chronic Graft-Versus-Host Disease Who Have Undergone a Previous Donor Stem Cell Transplant
|
| 551. |
XK469R in Treating Patients With Refractory Hematologic Cancer
|
| 552. |
Decitabine in Treating Patients With Myelofibrosis
|
| 553. |
Tirapazamine, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
|
| 554. |
Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer
|
| 555. |
UCN-01 and Topotecan in Treating Patients With Small Cell Lung Cancer That Relapsed or Progressed After Previous Chemotherapy
|
| 556. |
Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
|
| 557. |
NGR-TNF in Treating Patients With Advanced Solid Tumors
|
| 558. |
Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Stage IB, Stage II, or Stage IIIA Non-Small Cell Lung Cancer
|
| 559. |
Epratuzumab and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia
|
| 560. |
Carboplatin in Treating Patients With Stage IC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
| 561. |
VNP40101M in Treating Young Patients With Recurrent, Progressive, or Refractory Primary Brain Tumors
|
| 562. |
Thalidomide and Temozolomide in Treating Young Patients With Relapsed or Progressive Brain Tumors or Recurrent Neuroblastoma
|
| 563. |
SB-715992 in Treating Patients With Acute Leukemia, Chronic Myelogenous Leukemia, or Advanced Myelodysplastic Syndromes
|
| 564. |
FR901228 in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
|
| 565. |
Fenretinide in Preventing Ovarian Cancer in Participants Who Are at High Risk for Developing Ovarian Cancer and Planning to Undergo Surgery to Remove the Ovaries
|
| 566. |
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
| 567. |
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma
|
| 568. |
Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer
|
| 569. |
Fludarabine and Rituximab Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
|
| 570. |
Amifostine in Treating Young Patients With Newly Diagnosed De Novo Myelodysplastic Syndromes
|
| 571. |
Darbepoetin alfa in Treating Anemia in Patients With Non-Myeloid Cancer Who Are Not Receiving Chemotherapy
|
| 572. |
Sorafenib and Interferon alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
|
| 573. |
Doxorubicin and Flavopiridol in Treating Patients With Metastatic or Recurrent Sarcoma That Cannot Be Removed By Surgery
|
| 574. |
FR901228 and Flavopiridol in Treating Patients With Advanced Lung, Esophageal, or Pleural Cancer
|
| 575. |
Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors
|
| 576. |
Microsatellite Analysis of Urinary Sediment in Detecting Bladder Cancer
|
| 577. |
Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer
|
| 578. |
17-N-Allylamino-17-Demethoxygeldanamycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes
|
| 579. |
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
|
| 580. |
Vaccine Therapy in Treating Patients With Progressive or Locally Recurrent Prostate Cancer
|
| 581. |
Pemetrexed Disodium and Either Gemcitabine or Carboplatin in Treating Patients With Advanced Malignant Pleural Mesothelioma
|
| 582. |
Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer
|
| 583. |
Everolimus in Treating Patients With Stage IV Melanoma
|
| 584. |
Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer
|
| 585. |
Tipifarnib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
|
| 586. |
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
|
| 587. |
Temozolomide or Dacarbazine in Treating Patients With Stage IV Melanoma
|
| 588. |
Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma
|
| 589. |
SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma
|
| 590. |
Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
|
| 591. |
Vaccine Therapy in Treating Patients With Acute Myeloid Leukemia
|
| 592. |
Temozolomide and VNP40101M in Treating Patients With Relapsed or Refractory Leukemias
|
| 593. |
Oxaliplatin and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
|
| 594. |
MS-275 and Azacitidine in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia
|
| 595. |
Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma
|
| 596. |
Vaccine Therapy in Treating Patients With Stage IIIC or Stage IV Malignant Melanoma
|
| 597. |
Vaccine Therapy and Interleukin-2 After Combination Chemotherapy in Treating Patients With Relapsed or De Novo Stage II, Stage III, or Stage IV Mantle Cell Lymphoma
|
| 598. |
Pixantrone or Other Chemotherapy Drugs in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
|
| 599. |
Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer
|
| 600. |
Capecitabine and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Salivary Gland Cancer That Cannot Be Removed By Surgery
|
| 601. |
Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
|
| 602. |
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
|
| 603. |
Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer
|
| 604. |
Tretinoin and Interleukin-2 in Treating Patients With Stage IV Kidney Cancer
|
| 605. |
IH636 Grape Seed Extract in Preventing Breast Cancer in Postmenopausal Women at Risk of Developing Breast Cancer
|
| 606. |
Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
|
| 607. |
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
|
| 608. |
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
|
| 609. |
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
|
| 610. |
Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer
|
| 611. |
Irinotecan in Treating Patients With Metastatic or Inoperable Thyroid Cancer
|
| 612. |
Combination Chemotherapy, Bevacizumab, and Cetuximab in Treating Patients With Stage IV Colorectal Cancer That Cannot Be Removed by Surgery
|
| 613. |
Cilengitide in Treating Patients With Metastatic Prostate Cancer
|
| 614. |
Bortezomib With or Without Irinotecan in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
| 615. |
SJG-136 in Treating Patients With Advanced Solid Tumors
|
| 616. |
17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
|
| 617. |
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
|
| 618. |
Radiation Therapy in Treating Women Who Have Undergone Surgery For Ductal Carcinoma In Situ or Stage I or Stage II Breast Cancer
|
| 619. |
Sorafenib in Treating Patients With Recurrent or Progressive Stage IV Non-Small Cell Lung Cancer
|
| 620. |
Tipifarnib and Gemcitabine in Treating Women With Metastatic Breast Cancer
|
| 621. |
Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Non-Hodgkin's Lymphoma
|
| 622. |
Lapatinib in Treating Patients Who Are Undergoing Surgery for Recurrent Progressive Glioblastoma Multiforme or Gliosarcoma
|
| 623. |
Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer
|
| 624. |
Photodynamic Therapy Using Silicon Phthalocyanine 4 in Treating Patients With Actinic Keratosis, Bowen's Disease, Skin Cancer, or Stage I or Stage II Mycosis Fungoides
|
| 625. |
Vaccine Therapy in Treating Patients With Liver Metastases From Colorectal Cancer
|
| 626. |
Imatinib Mesylate or Observation Only in Treating Patients Who Have Undergone Surgery for Localized Gastrointestinal Stromal Tumor
|
| 627. |
Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer
|
| 628. |
Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
|
| 629. |
Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
|
| 630. |
Lenalidomide in Treating Young Patients With Relapsed or Refractory Solid Tumors or Myelodysplastic Syndromes
|
| 631. |
Trastuzumab in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma
|
| 632. |
Androgen Deprivation Therapy in Treating Patients With Prostate Cancer
|
| 633. |
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
|
| 634. |
Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
|
| 635. |
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction
|
| 636. |
Colonoscopy or Fecal Occult Blood Test in Screening Healthy Participants for Colorectal Cancer
|
| 637. |
Radiotherapy or Radiosurgery Compared With Observation Alone in Treating Patients With Newly Diagnosed, Benign Meningioma That Has Been Partially Removed by Surgery
|
| 638. |
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma
|
| 639. |
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy
|
| 640. |
Surgery in Treating Patients With Resectable Pancreatic Neoplasms
|
| 641. |
Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma That Did Not Respond to Fludarabine
|
| 642. |
Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma
|
| 643. |
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
|
| 644. |
Irinotecan and Carboplatin in Treating Patients With Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
|
| 645. |
Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
|
| 646. |
Proton Beam Radiation Therapy in Treating Young Patients Who Have Undergone Biopsy or Surgery for Medulloblastoma or Pineoblastoma
|
| 647. |
Pemetrexed Disodium in Treating Patients With Recurrent and Unresectable or Metastatic Chondrosarcoma
|
| 648. |
Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
|
| 649. |
Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
|
| 650. |
Triptorelin, Flutamide, and External-Beam Radiation Therapy or External-Beam Radiation Therapy Alone in Treating Patients With Stage II or Stage III Prostate Cancer
|
| 651. |
Hormone Therapy and Docetaxel or Hormone Therapy Alone in Treating Patients With Metastatic Prostate Cancer
|
| 652. |
Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
|
| 653. |
Radiation Therapy in Treating Older Women Who Are Undergoing Surgery for Stage I or Stage II Breast Cancer
|
| 654. |
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
|
| 655. |
Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast
|
| 656. |
Radiation Therapy in Treating Women With Localized Breast Cancer
|
| 657. |
Docetaxel in Treating Older Women With Metastatic Breast Cancer
|
| 658. |
Topotecan, G-CSF, and Radiation Therapy in Treating Young Patients With Newly Diagnosed Brain Stem Glioma
|
| 659. |
Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors
|
| 660. |
Yttrium Y 90 DOTA Monoclonal Antibody HuPAM4 in Treating Patients With Stage III or Stage IV Pancreatic Cancer
|
| 661. |
Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin's Disease
|
| 662. |
Lapatinib in Treating Patients With Unresectable Liver or Biliary Tract Cancer
|
| 663. |
Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma
|
| 664. |
Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
|
| 665. |
AMG 706, Panitumumab, and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
|
| 666. |
Iodine I 131 Metaiodobenzylguanidine and Arsenic Trioxide in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
|
| 667. |
Combination Chemotherapy and Cyclosporine Followed By Cryotherapy and/or Laser Therapy in Treating Patients With Newly Diagnosed Retinoblastoma in Both Eyes
|
| 668. |
Surgery With or Without Internal Radiation Therapy in Treating Patients With Stage I Non-Small Cell Lung Cancer
|
| 669. |
Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma
|
| 670. |
AZD2171 and Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)
|
| 671. |
Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Peritoneal Cancer
|
| 672. |
Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma
|
| 673. |
Vaccine Therapy and GM-CSF in Treating Patients With Prostate Cancer That Progressed After Surgery and/or Radiation Therapy
|
| 674. |
Cyclophosphamide and Capecitabine in Treating Women With Stage IV Breast Cancer
|
| 675. |
Iodine I 131 Tositumomab and Fludarabine in Treating Older Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's Lymphoma
|
| 676. |
Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors
|
| 677. |
Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia
|
| 678. |
Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma
|
| 679. |
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
|
| 680. |
Positron Emission Tomography Using Fludeoxyglucose F 18 in Predicting Response to Treatment in Patients Who Are Receiving Rituximab and Combination Chemotherapy for Newly Diagnosed Non-Hodgkin's Lymphoma
|
| 681. |
Alemtuzumab, Tacrolimus, and Methylprednisolone in Treating Acute Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant
|
| 682. |
Vaccine Therapy in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer
|
| 683. |
Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
|
| 684. |
CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
| 685. |
Monoclonal Antibody hA20 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
|
| 686. |
Opioid Growth Factor in Treating Patients With Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
|
| 687. |
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Peripheral T-Cell Non-Hodgkin's Lymphoma
|
| 688. |
Melphalan and Prednisone With or Without Bortezomib in Treating Older Patients With Newly Diagnosed Multiple Myeloma
|
| 689. |
S-1 and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage III Stomach Cancer
|
| 690. |
Radiofrequency Ablation in Treating Patients With Stage I Non-Small Cell Lung Cancer
|
| 691. |
Magnetic Resonance Imaging and Fludeoxyglucose F18 Positron Emission Tomography in Diagnosing Patients With Solitary Plasmacytoma
|
| 692. |
Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma
|
| 693. |
Cetuximab, Combination Chemotherapy, and Radiation therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery
|
| 694. |
Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
|
| 695. |
Decitabine With or Without Valproic Acid in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
| 696. |
Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
|
| 697. |
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
|
| 698. |
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
|
| 699. |
Temozolomide and Topotecan in Treating Patients With Primary CNS Lymphoma
|
| 700. |
Irinotecan and Selenium in Treating Patients With Advanced Solid Tumors
|
| 701. |
Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer
|
| 702. |
Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
|
| 703. |
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
|
| 704. |
Melphalan and Radiation Therapy Followed By Dexamethasone and Thalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
|
| 705. |
Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Stage 0, Stage I, or Stage II Breast Cancer
|
| 706. |
Enzastaurin in Treating Patients With Recurrent Gliomas
|
| 707. |
Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer
|
| 708. |
Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery
|
| 709. |
Green Tea Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus
|
| 710. |
Tamoxifen and Bortezomib in Treating Patients With Recurrent Gliomas
|
| 711. |
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
|
| 712. |
Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
|
| 713. |
Flavopiridol in Treating Patients With Locally Advanced or Metastatic Solid Tumors
|
| 714. |
Bowman Birk Inhibitor Concentrate in Preventing Cancer in Healthy Men
|
| 715. |
Gemcitabine in Combination With Either Cisplatin or Carboplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
| 716. |
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract
|
| 717. |
Radiation Therapy and Docetaxel With Either Fluorouracil or Cisplatin as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
|
| 718. |
Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
|
| 719. |
Donor Stem Cell Transplant in Treating Young Patients With Relapsed or Refractory Solid Tumors
|
| 720. |
Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor
|
| 721. |
Topotecan in Treating Young Patients With Neoplastic Meningitis Due to Leukemia, Lymphoma, or Solid Tumors
|
| 722. |
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
| 723. |
Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
|
| 724. |
Fludarabine and Total-Body Irradiation Followed By a Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
| 725. |
MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By Surgery
|
| 726. |
Lenalidomide in Treating Patients With Stage IV Eye Melanoma
|
| 727. |
Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia
|
| 728. |
Iodine I 131 Monoclonal Antibody BC8, Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndromes
|
| 729. |
Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer
|
| 730. |
Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes
|
| 731. |
Alemtuzumab, Fludarabine, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
|
| 732. |
Lapatinib in Treating Patients With Metastatic or Recurrent Head and Neck Cancer
|
| 733. |
Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, Stage III, or Stage IV Melanoma
|
| 734. |
Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
| 735. |
Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
|
| 736. |
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
|
| 737. |
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
|
| 738. |
Azacitidine and Etanercept in Treating Patients With Myelodysplastic Syndromes
|
| 739. |
Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Chronic Myelogenous Leukemia
|
| 740. |
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
|
| 741. |
FR901228 in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
|
| 742. |
Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer
|
| 743. |
Erlotinib, Combination Chemotherapy, and Bevacizumab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
|
| 744. |
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
|
| 745. |
17-AAG in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer
|
| 746. |
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
|
| 747. |
Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer
|
| 748. |
Proteomic Profiling in Predicting Relapse in Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
|
| 749. |
Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
| 750. |
Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin's Lymphoma With or Without Impaired Liver or Kidney Function
|
| 751. |
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
|
| 752. |
Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
|
| 753. |
Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
|
| 754. |
Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
| 755. |
Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients Who Are Undergoing Surgery for Liver Metastases Due to Colorectal Cancer
|
| 756. |
Calcitriol in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia
|
| 757. |
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
|
| 758. |
Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
|
| 759. |
Isotretinoin, Interferon alfa-2b, and Paclitaxel in Treating Patients With Stage IV, Recurrent, or Persistent Cervical Cancer
|
| 760. |
Genistein in Treating Patients Who Are Undergoing Surgery for Bladder Cancer
|
| 761. |
17-AAG in Treating Patients With Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Hodgkin's Lymphoma
|
| 762. |
Methotrexate, Trimetrexate Glucuronate, and Leucovorin in Treating Patients With Refractory or Recurrent Osteosarcoma
|
| 763. |
17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors
|
| 764. |
Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
|
| 765. |
Bevacizumab and Combination Chemotherapy in Treating Patients Who Have Undergone Surgery for Breast Cancer That Has Spread to the Lymph Nodes
|
| 766. |
SJG-136 in Treating Patients With Metastatic or Unresectable Solid Tumors
|
| 767. |
Combination Chemotherapy, Rituximab, and Bevacizumab in Treating Older Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
|
| 768. |
Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer
|
| 769. |
17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors
|
| 770. |
Sorafenib and Bevacizumab in Treating Patients With Advanced Kidney Cancer
|
| 771. |
Gemcitabine and Docetaxel in Treating Patients With Recurrent or Persistent Uterine Cancer
|
| 772. |
Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Multiple Myeloma
|
| 773. |
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
|
| 774. |
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
|
| 775. |
Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
|
| 776. |
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
|
| 777. |
Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer
|
| 778. |
Positron Emission Tomography Using Carbon-11 Acetate in Finding Metastases and Predicting Recurrence in Patients With Newly Diagnosed Prostate Cancer Who Are at Risk for Recurrence After Treatment
|
| 779. |
Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
| 780. |
Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma
|
| 781. |
Vaccine Therapy in Treating Patients With Stage IV Melanoma
|
| 782. |
Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer
|
| 783. |
Docetaxel With or Without Dimethylxanthenone Acetic Acid (AS1404) in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
|
| 784. |
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
|
| 785. |
Suberoylanilide Hydroxamic Acid in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
|
| 786. |
Zoledronate, Clodronate, or Ibandronate in Treating Women Who Have Undergone Surgery for Stage I, Stage II, or Stage III Breast Cancer
|
| 787. |
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
|
| 788. |
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer
|
| 789. |
Erlotinib With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
| 790. |
Combination Chemotherapy and Tipifarnib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
|
| 791. |
Temozolomide and Radiation Therapy With or Without Vatalanib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
| 792. |
Vaccine Therapy, MDX-010, and GM-CSF in Treating Patients With Metastatic Prostate Cancer
|
| 793. |
Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
|
| 794. |
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
|
| 795. |
Sorafenib With or Without Interferon alfa-2b in Treating Patients With Metastatic Kidney Cancer
|
| 796. |
Trastuzumab in Treating Patients With Metastatic or Recurrent Salivary Gland Cancer
|
| 797. |
Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors
|
| 798. |
Gemcitabine, Cisplatin, and Bevacizumab in Treating Patients With Metastatic Pancreatic Cancer
|
| 799. |
Sorafenib in Treating Patients With Recurrent Diffuse Large B-Cell Non-Hodgkin's Lymphoma
|
| 800. |
Bevacizumab and Combination Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer
|
| 801. |
Bortezomib, Rituximab, and Combination Chemotherapy in Treating Patients With Mantle Cell Lymphoma
|
| 802. |
Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
|
| 803. |
BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma
|
| 804. |
Doxorubicin, Cyclophosphamide, and/or Paclitaxel in Treating Women With Nonmetastatic Breast Cancer
|
| 805. |
Cilengitide in Treating Patients With Prostate Cancer
|
| 806. |
Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer
|
| 807. |
Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia
|
| 808. |
Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma
|
| 809. |
Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
|
| 810. |
Iodine I 131 Monoclonal Antibody TNT-1/B in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
|
| 811. |
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
|
| 812. |
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
|
| 813. |
Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
|
| 814. |
Fulvestrant and/or Trastuzumab as First-Line Therapy in Treating Postmenopausal Women With Stage IV Breast Cancer
|
| 815. |
Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy
|
| 816. |
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
|
| 817. |
Radiofrequency Ablation in Treating Patients With Liver Cancer and Cirrhosis
|
| 818. |
Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
| 819. |
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma
|
| 820. |
Amrubicin and Irinotecan in Treating Patients With Recurrent or Relapsed Extensive Stage Small Cell Lung Cancer
|
| 821. |
S-1 and Irinotecan in Treating Patients Who Are Undergoing Surgery for Locally Advanced Stomach Cancer
|
| 822. |
PI-88 and/or Dacarbazine in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery
|
| 823. |
Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
|
| 824. |
Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx
|
| 825. |
Magnetic Resonance Imaging in Evaluating Patients With Prostate Cancer
|
| 826. |
Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Leukemia
|
| 827. |
Topotecan in Treating Patients With Metastatic or Unresectable Solid Tumors
|
| 828. |
Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone a Previous Autologous or Syngeneic Bone Marrow or Stem Cell Transplant for Multiple Myeloma
|
| 829. |
Vaccine Therapy, GM-CSF, and Interferon alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)
|
| 830. |
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
|
| 831. |
Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
|
| 832. |
Denileukin Diftitox in Treating Patients With Adult T-Cell Leukemia/Lymphoma
|
| 833. |
Cisplatin, Fluorouracil, Cetuximab, and Radiation Therapy in Treating Patients With HIV and Stage I, Stage II, or Stage III Anal Cancer
|
| 834. |
Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
|
| 835. |
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
| 836. |
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
|
| 837. |
Sirolimus in Treating Patients With Angiomyolipoma of the Kidney
|
| 838. |
Combination Chemotherapy With or Without Cetuximab as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
|
| 839. |
Radiation Therapy During Surgery in Treating Older Women With Invasive Breast Cancer
|
| 840. |
Combination Chemotherapy, Tacrolimus, and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant For Hematologic Cancer
|
| 841. |
Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma
|
| 842. |
Octreotide in Treating Patients With Cancer-Related Malignant Ascites
|
| 843. |
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
|
| 844. |
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
|
| 845. |
Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia
|
| 846. |
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
|
| 847. |
Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
|
| 848. |
Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin's Lymphoma
|
| 849. |
Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis
|
| 850. |
Risk Factors for Developing a Blood Clot in Patients Who Are Undergoing Cancer Treatment for Newly Diagnosed Gliomas
|
| 851. |
Ixabepilone and Liposomal Doxorubicin in Treating Women With Advanced Ovarian Epithelial, Peritoneal Cavity, or Fallopian Tube Cancer or Metastatic Breast Cancer
|
| 852. |
G-CSF in Stimulating Peripheral Stem Cells for Autologous Stem Cell Transplant in Treating Patients With Chronic Phase Chronic Myeloid Leukemia in Complete Remission
|
| 853. |
Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy
|
| 854. |
Melphalan and Amifostine Followed By One or Two Autologous or Syngeneic Stem Cell Transplants and Maintenance Therapy in Treating Patients With Stage II or Stage III Multiple Myeloma
|
| 855. |
An Individualized Internet-Based Health Behavior Program or a Standard Internet-Based Health Behavior Program in Preventing Cancer and Improving Physical Activity and Nutrition in Participants Who Are Physically Inactive With a Higher Body Mass Index
|
| 856. |
Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Breast Cancer in Remission
|
| 857. |
Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma
|
| 858. |
Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
|
| 859. |
S-1 and Cisplatin or Fluorouracil and Cisplatin in Treating Patients With Locally Advanced or Metastatic Gastric Cancer That Cannot Be Removed By Surgery
|
| 860. |
Vaccine Therapy in Preventing Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants
|
| 861. |
Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms
|
| 862. |
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors
|
| 863. |
Photodynamic Therapy in Treating Patients With Precancerous Esophageal Conditions or Early Stage Esophageal Cancer
|
| 864. |
Fulvestrant in Treating Patients With Recurrent Prostate Cancer
|
| 865. |
Paricalcitol and Gemcitabine in Treating Patients With Advanced Cancer
|
| 866. |
Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma
|
| 867. |
Selenium in Treating Patients Who Are Undergoing Brachytherapy for Stage I or Stage II Prostate Cancer
|
| 868. |
Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer
|
| 869. |
Positron Emission Tomography in Predicting Response in Patients Who Are Undergoing Treatment With Pemetrexed Disodium and Cisplatin With or Without Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
|
| 870. |
Rituximab and Dexamethasone in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
|
| 871. |
Azacitidine and Interferon alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery
|
| 872. |
Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer
|
| 873. |
Paclitaxel in Treating Patients With Locally Advanced or Metastatic Soft Tissue Angiosarcoma or Lymphangiosarcoma That Cannot Be Removed By Surgery
|
| 874. |
Celecoxib in Treating Patients With Familial Adenomatous Polyposis
|
| 875. |
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
|
| 876. |
Alemtuzumab and Cyclosporine in Treating Patients With Myelodysplastic Syndromes
|
| 877. |
S-1 as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer
|
| 878. |
S-1 as Second-Line Therapy in Treating Patients With Unresectable or Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer
|
| 879. |
Tandem Stem Cell Transplantation in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
|
| 880. |
Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer
|
| 881. |
Radiation Therapy or Temozolomide in Treating Patients With Gliomas
|
| 882. |
Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
|
| 883. |
Docetaxel With or Without Vaccine Therapy and GM-CSF in Treating Patients With Metastatic Breast Cancer
|
| 884. |
MRI-Guided Radiation Therapy in Treating Patients With Prostate Cancer
|
| 885. |
Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia
|
| 886. |
Pemetrexed Disodium and Carboplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
|
| 887. |
Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That Has Relapsed After Previous Rituximab Treatment
|
| 888. |
Docetaxel With or Without Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer
|
| 889. |
Bevacizumab and Capecitabine in Treating Frail Patients With Metastatic Colorectal Cancer
|
| 890. |
Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer
|
| 891. |
Goserelin and Anastrozole in Treating Men With Recurrent or Metastatic Breast Cancer
|
| 892. |
Computer-Based Survey and Communication Aid in Improving Physician-Patient Communication and Treatment Decision Making in Patients With Metastatic Cancer
|
| 893. |
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
|
| 894. |
Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes
|
| 895. |
Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
|
| 896. |
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
|
| 897. |
Etoposide and Cyclophosphamide in Treating Patients With Stage D0 Prostate Cancer
|
| 898. |
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
|
| 899. |
Capecitabine and Pegylated Interferon alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer
|
| 900. |
Docetaxel in Treating Older Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
| 901. |
Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma
|
| 902. |
Fish Oil in Preventing Prostate Cancer in Patients With Prostatic Intraepithelial Neoplasia or Who Are at Risk for Developing Prostate Cancer
|
| 903. |
Metoclopramide in Treating Patients With Anemia Due to Myelodysplastic Syndromes
|
| 904. |
Rituximab in Preventing Chronic Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma
|
| 905. |
Oxaliplatin, Irinotecan, and Capecitabine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
|
| 906. |
Radiation Therapy and Capecitabine With or Without Oxaliplatin in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Rectal Cancer
|
| 907. |
Melphalan and Mannitol in Treating Patients With Central Nervous System Cancer
|
| 908. |
Denileukin Diftitox in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
|
| 909. |
Calcitriol and Docetaxel in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer
|
| 910. |
Radiation Therapy in Treating Young Patients With Gliomas
|
| 911. |
Acupuncture in Treating Hot Flashes in Patients With Prostate Cancer
|
| 912. |
Sorafenib in Treating Patients With Advanced or Recurrent Uterine Cancer
|
| 913. |
Chemosensitivity Assays in Predicting Response to Chemotherapy in Patients With Persistent, Refractory, or Recurrent Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer
|
| 914. |
Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Esophageal Cancer
|
| 915. |
Temozolomide During and After Radiation Therapy in Treating Patients Who Have Undergone Previous Surgery and Placement of Gliadel Wafers for Newly Diagnosed Glioblastoma Multiforme
|
| 916. |
Radiation Therapy Combined With Either Gefitinib or Temozolomide in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases
|
| 917. |
Transdermal Estradiol in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy and Chemotherapy
|
| 918. |
Rituximab, Temozolomide, and Methylprednisolone in Treating Patients With Recurrent Primary CNS Non-Hodgkin's Lymphoma
|
| 919. |
Trastuzumab and Letrozole in Treating Postmenopausal Women With Progressive Advanced Breast Cancer
|
| 920. |
Treosulfan and Fludarabine in Treating Younger Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
|
| 921. |
Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
|
| 922. |
Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer
|
| 923. |
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
|
| 924. |
Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer
|
| 925. |
Vaccine Therapy in Treating Patients Who Are Being Considered For a Solid Organ Transplant and Are at Risk For Post-Transplant Lymphoproliferative Disorder
|
| 926. |
Imatinib Mesylate in Treating Patients With Myelofibrosis
|
| 927. |
Proteomic Profiling in Diagnosing Ovarian Cancer in Patients Who Are Undergoing Surgery for an Abnormal Pelvic Mass
|
| 928. |
AZD2171 in Treating Patients With Refractory Stage IV Breast Cancer
|
| 929. |
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
|
| 930. |
Aprepitant, Ondansetron, and Dexamethasone in Preventing Nausea and Vomiting in Patients Who Are Undergoing a Stem Cell Transplant
|
| 931. |
Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
|
| 932. |
Capecitabine in Treating Patients Who Have Undergone Previous Surgery, Radiation Therapy, and/or Chemotherapy for Head and Neck Cancer
|
| 933. |
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
|
| 934. |
Boswellia serrata Combined With a Low-Fat, Vegan Diet or a Standard Diet Alone in Treating Patients Who Have Undergone Surgery and Radiation Therapy for Newly Diagnosed or Recurrent High-Grade Glioma
|
| 935. |
Capecitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
|
| 936. |
Fludeoxyglucose F 18 Positron Emission Tomography in Predicting Risk of Relapse in Patients With Non-Hodgkin's Lymphoma Who Are Undergoing Combination Chemotherapy With or Without Autologous Stem Cell or Bone Marrow Transplant
|
| 937. |
Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems
|
| 938. |
Glutamine in Preventing Myalgia and/or Arthralgia in Patients Who Are Receiving Paclitaxel For Cancer
|
| 939. |
Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin
|
| 940. |
Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Cannot Be Removed By Surgery
|
| 941. |
Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors
|
| 942. |
Rectal Reconstruction in Treating Patients Who Are Undergoing Surgery for Rectal Cancer
|
| 943. |
Carboplatin, Pemetrexed Disodium, and Bevacizumab in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
|
| 944. |
Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma
|
| 945. |
AZD2171 in Treating Patients With Progressive Locally Recurrent or Metastatic Kidney Cancer That Cannot Be Removed By Surgery
|
| 946. |
AZD2171 in Treating Patients With Locally Advanced or Metastatic Liver Cancer
|
| 947. |
Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma
|
| 948. |
Radiation Therapy, Cyclophosphamide, and Doxorubicin in Treating Women With Stage I or Stage II Breast Cancer Who Have Undergone Surgery
|
| 949. |
Busulfan, Melphalan, and Thiotepa in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Hodgkin's or Non-Hodgkin's Lymphoma
|
| 950. |
Hormone Therapy With or Without Squalamine Lactate in Treating Patients Who Are Undergoing a Radical Prostatectomy for Locally Advanced Prostate Cancer
|
| 951. |
Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer
|
| 952. |
Gemcitabine Hydrochloride and Genistein in Treating Women With Stage IV Breast Cancer
|
| 953. |
Interferon alfa in Treating Patients
With Metastatic Kidney Cancer
|
| 954. |
BI 2536 in Treating Patients With Refractory or Relapsed Advanced Non-Hodgkin's Lymphoma
|
| 955. |
AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
|
| 956. |
Loop Resectoscope in Treating Patients With Bladder Cancer or Benign Prostatic Hyperplasia Who Are Undergoing Transurethral Resection
|
| 957. |
Anastrozole in Treating Postmenopausal Women Who Have Undergone Surgery for Ductal Carcinoma in Situ or Stage I, Stage II, or Stage III Breast Cancer
|
| 958. |
Capecitabine in Treating Patients With Metastatic Breast Cancer
|
| 959. |
Gemcitabine and Mitoxantrone in Treating Patients With Relapsed Acute Myeloid Leukemia
|
| 960. |
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
|
| 961. |
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
|
| 962. |
Autologous Stem Cell Transplant in Treating Patients With Progressive or Recurrent Hodgkin's Lymphoma
|
| 963. |
Fludarabine and Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Peripheral Stem Cell Transplant for Hematologic Cancer
|
| 964. |
Imatinib Mesylate, Daunorubicin, and Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia
|
| 965. |
AZD2171 in Treating Patients With Recurrent or Stage IV Melanoma
|
| 966. |
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
|
| 967. |
Tipifarnib and Sorafenib in Treating Patients With Advanced Cancer
|
| 968. |
Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Chronic Idiopathic Myelofibrosis or Myelodysplastic or Myeloproliferative Disorders
|
| 969. |
Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer
|
| 970. |
Erlotinib, Paclitaxel, and Carboplatin Combined With Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
|
| 971. |
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders
|
| 972. |
Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer
|
| 973. |
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
| 974. |
Samarium Sm 153 Lexidronam Pentasodium and Autologous Stem Cell Transplant Followed By Radiation Therapy in Treating Patients With Recurrent or Refractory, Metastatic, or Unresectable Osteosarcoma
|
| 975. |
Sulindac in Preventing Breast Cancer in Women at High Risk for Breast Cancer
|
| 976. |
Rituximab, Cyclophosphamide, and G-CSF Followed By Combination Chemotherapy in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant Followed By Rituximab and GM-CSF for Refractory Diffuse Large B-Cell Lymphoma
|
| 977. |
Gefitinib in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer That Can Be Removed By Surgery
|
| 978. |
Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Prostate Cancer
|
| 979. |
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
|
| 980. |
Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders
|
| 981. |
Fludarabine and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Progressive Metastatic Prostate Cancer That Has Not Responded to Previous Hormone Therapy
|
| 982. |
Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery
|
| 983. |
Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
|
| 984. |
AZD2171 in Treating Patients With Recurrent Small Cell Lung Cancer
|
| 985. |
Stereotactic Radiosurgery and Radiation Therapy in Treating Patients With Glioblastoma Multiforme
|
| 986. |
GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer
|
| 987. |
Pyridoxine in Preventing Hand-Foot Syndrome in Patients Who Are Receiving Liposomal Doxorubicin for Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer, Metastatic Breast Cancer, or Advanced Endometrial Cancer
|
| 988. |
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
|
| 989. |
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
|
| 990. |
Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia
|
| 991. |
Positron Emission Tomography Using 11C Topotecan in Predicting Response to Treatment in Patients With Brain Metastases Due to Ovarian, Small Cell Lung, or Other Cancer
|
| 992. |
Quality of life of Older Patients Who Are Undergoing Treatment for Cancer and of Their Family Caregivers
|
| 993. |
Nerve Function in Older Diabetic Patients Who Are Undergoing Chemotherapy for Metastatic Solid Tumors
|
| 994. |
Temozolomide in Treating Patients With Low-Grade Glioma
|
| 995. |
Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors
|
| 996. |
Cyclophosphamide and/or Mycophenolate Mofetil With or Without Tacrolimus in Treating Patients Who Are Undergoing a Donor Bone Marrow or Peripheral Stem Cell Transplant for Hematologic Cancer
|
| 997. |
Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
|
| 998. |
Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma
|
| 999. |
Bortezomib in Treating Patients With Myelodysplastic Syndromes
|
| 1000. |
Radiotherapy, Combination Chemotherapy, and Gefitinib Before and After Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer
|
| 1001. |
Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
|
| 1002. |
NB1011 in Treating Patients With Advanced, Recurrent, or Metastatic Solid Tumors
|
| 1003. |
Donor Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Relapsed or Refractory Metastatic Kidney Cancer
|
| 1004. |
Combination Chemotherapy and Radiation Therapy in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
|
| 1005. |
Capecitabine, Cetuximab, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic or Recurrent Colorectal Cancer That Cannot Be Removed By Surgery
|
| 1006. |
Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
|
| 1007. |
ABT-510 and Bevacizumab in Treating Patients With Advanced Solid Tumors
|
| 1008. |
Combination Chemotherapy and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed or Refractory Hodgkin's Lymphoma
|
| 1009. |
Sorafenib in Treating Patients with Metastatic, Locally Advanced, or Recurrent Sarcoma
|
| 1010. |
Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
|
| 1011. |
Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
|
| 1012. |
Bevacizumab, Everolimus, and Erlotinib in Treating Patients With Advanced Solid Tumors
|
| 1013. |
Radiation Therapy With or Without Vinorelbine and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer
|
| 1014. |
Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
|
| 1015. |
Caregiver Support in the Coping of Patients Who Are Undergoing a Donor Bone Marrow Transplant
|
| 1016. |
Vorinostat in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
|
| 1017. |
Etanercept, Mycophenolate Mofetil, Denileukin Diftitox, or Pentostatin Combined With Prednisone or Methylprednisolone in Treating Patients With Acute Graft-Versus-Host Disease Who Have Undergone a Previous Donor Stem Cell Transplant
|
| 1018. |
Caregiver Support in the Quality of Life of Patients Who are Undergoing Donor Bone Marrow Transplantation
|
| 1019. |
Iodine I 131 metaiodobenzylguanidine, Combination Chemotherapy, and Radiation Therapy in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell or Bone Marrow Transplant for Relapsed or Refractory Neuroblastoma
|
| 1020. |
Genetic Counseling or Usual Care in Helping Women With Newly Diagnosed Ductal Carcinoma In Situ or Stage I, Stage II, or Stage IIIA Breast Cancer Make Treatment Decisions
|
| 1021. |
Broccoli Sprout Extract in Preventing Lung Cancer in Smokers
|
| 1022. |
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer
|
| 1023. |
Floxuridine and Dexamethasone as a Hepatic Arterial Infusion and Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Liver Metastases Due to Colorectal Cancer
|
| 1024. |
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas
|
| 1025. |
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
|
| 1026. |
Radiation Therapy in Treating Patients With Liver Metastases
|
| 1027. |
Observation of Young Patients Who Are Undergoing Surgery for Craniopharyngioma
|
| 1028. |
Donor Natural Killer Cell Infusion in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
|
| 1029. |
Cyclophosphamide and Melphalan Followed By an Autologous Stem Cell Transplant, Dexamethasone, and Thalidomide in Treating Patients With Previously Treated Multiple Myeloma
|
| 1030. |
Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
|
| 1031. |
Low-Residue Diet in Treating Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis for Uterine, Cervical, or Prostate Cancer
|
| 1032. |
Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
|
| 1033. |
Bevacizumab and Irinotecan in Treating Patients With Recurrent or Refractory Gliomas
|
| 1034. |
Combination Chemotherapy in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Fanconi's Anemia
|
| 1035. |
Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
| 1036. |
AZD0530 and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
|
| 1037. |
Docetaxel and Prednisone With or Without OGX-011 in Treating Patients With Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
|
| 1038. |
OGX-011 and Docetaxel in Treating Women With Locally Advanced or Metastatic Breast Cancer
|
| 1039. |
Paclitaxel and Carboplatin With or Without AZD2171 in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
| 1040. |
Combination Chemotherapy, Radiation Therapy, and Interferon alfa in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed By Surgery
|
| 1041. |
Donor Peripheral Stem Cell Transplant in Treating Patients With Relapsed Acute Myeloid Leukemia
|
| 1042. |
Zoledronate and Cyclophosphamide in Treating Young Patients With Recurrent, Refractory, or Persistent Neuroblastoma and Bone Metastases
|
| 1043. |
Cyclophosphamide, Fludarabine, and Donor White Blood Cells in Treating Patients With Hematologic Cancer That Relapsed After a Previous Donor Stem Cell Transplant
|
| 1044. |
Combination Chemotherapy and Radiation Therapy Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer
|
| 1045. |
Bevacizumab, Docetaxel, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
|
| 1046. |
Internal Radiation Therapy After Lumpectomy in Treating Women With Ductal Carcinoma in Situ
|
| 1047. |
Carboplatin, Gemcitabine, and Thalidomide in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Non-Small Cell Lung Cancer
|
| 1048. |
Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation
|
| 1049. |
Nerve Changes in Patients Who Are Undergoing Chemotherapy or Biological Therapy for Cancer
|
| 1050. |
Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors
|
| 1051. |
Busulfan, Cyclophosphamide, Melphalan, and Donor Stem Cell Transplant in Treating Young Patients For Juvenile Myelomonocytic Leukemia
|
| 1052. |
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
|
| 1053. |
Donor Umbilical Cord Blood Transplant By Injection into the Bone Marrow in Treating Patients With Hematologic Cancer
|
| 1054. |
Hypnosis, Massage Therapy, and Healing Touch in Treating Patients Receiving Chemotherapy for Ovarian Epithelial Cancer or Peritoneal Cavity Cancer
|
| 1055. |
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer
|
| 1056. |
Vinflunine in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium
|
| 1057. |
Erlotinib in Treating Patients With Metastatic and/or Recurrent Head and Neck Cancer
|
| 1058. |
Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
|
| 1059. |
Computer Program in Improving Communication Between Doctors and Patients With Stage IV Cancer
|
| 1060. |
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
|
| 1061. |
Early Intervention Palliative Care or a Standard Palliative Care Program in Improving End-of-Life Care in Patients With Advanced Lung, Gastrointestinal, Genitourinary, or Breast Cancer
|
| 1062. |
Personalized Nutrition Education in Improving Eating Habits of Healthy Participants Who Eat an Unhealthy Diet
|
| 1063. |
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
|
| 1064. |
Bortezomib in Treating Patients With Metastatic Kidney Cancer
|
| 1065. |
Autologous Peripheral Stem Cell or Bone Marrow Transplant Using Laboratory-Treated Cells in Treating Patients With Acute Leukemia
|
| 1066. |
Combination Chemotherapy and Radiation Therapy in Treating Patients With Recurrent Metastatic Colorectal Cancer
|
| 1067. |
Combination Chemotherapy in Treating Patients With Colorectal Cancer and Liver Metastases
|
| 1068. |
Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery
|
| 1069. |
Combination Chemotherapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
|
| 1070. |
Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer
|
| 1071. |
Combination Chemotherapy as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
|
| 1072. |
Irinotecan With or Without Capecitabine as Second-Line Therapy in Treating Older Patients With Progressive, Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
|
| 1073. |
Combination Chemotherapy and Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
|
| 1074. |
Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
|
| 1075. |
Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Cancer
|
| 1076. |
Celecoxib or Observation After Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-Small Cell Lung Cancer
|
| 1077. |
Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer
|
| 1078. |
Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated Diffuse Large B-Cell Lymphoma
|
| 1079. |
Radiation Therapy or Combination Chemotherapy in Treating Patients With Clinically or Radiologically Progressive Low-Grade Gliomas
|
| 1080. |
Prednisolone or Dexamethasone Combined With Chemotherapy in Treating Young Patients With Newly Diagnosed Lymphoblastic Lymphoma
|
| 1081. |
Radiation Therapy Followed By Combination Chemotherapy in Treating Young Patients With Supratentorial Primitive Neuroectodermal Tumors
|
| 1082. |
Etoposide in Treating Young Patients With Relapsed Ependymoma
|
| 1083. |
High-Dose Methotrexate in Treating Young Patients With Residual Ependymoma
|
| 1084. |
Radiation Therapy and Combination Chemotherapy in Treating Young Patients With Metastatic Medulloblastoma Who Have Undergone Surgery
|
| 1085. |
Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma
|
| 1086. |
Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors
|
| 1087. |
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
|
| 1088. |
Fludarabine and Darbepoetin alfa in Treating Older Patients With Chronic Lymphocytic Leukemia
|
| 1089. |
Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer
|
| 1090. |
Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia
|
| 1091. |
Combination Chemotherapy Followed By Alemtuzumab in Treating Patients with Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia
|
| 1092. |
Methotrexate as First-Line Therapy and Fludarabine as Second-Line Therapy in Treating Patients With T-Cell Large Granular Lymphocytic Leukemia
|
| 1093. |
Combination Chemotherapy in Treating Young Patients With Advanced Solid Tumors
|
| 1094. |
Computer-Based Continuing Education for Doctors in Examination and Counseling of Patients on Skin Cancer or Weight Control
|
| 1095. |
Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas
|
| 1096. |
Irinotecan in Treating Young Patients With Refractory or Recurrent Hepatoblastoma
|
| 1097. |
Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis
|
| 1098. |
Liposomal Doxorubicin Followed By Bexarotene in Treating Patients With Cutaneous T-Cell Lymphoma
|
| 1099. |
Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer
|
| 1100. |
Radiation Therapy and Temozolomide Followed by Temozolomide and Poly ICLC in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
| 1101. |
Topotecan and Vinorelbine in Treating Patients With Recurrent Lung Cancer
|
| 1102. |
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
|
| 1103. |
Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
|
| 1104. |
Cisplatin, Bevacizumab, and Gemcitabine Followed by Surgery, Bevacizumab, and Paclitaxel in Treating Patients With Locally Advanced Nonmetastatic Bladder Cancer That Can Be Removed By Surgery
|
| 1105. |
Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors
|
| 1106. |
Lapatinib in Treating Patients With Relapsed or Refractory Inflammatory Breast Cancer
|
| 1107. |
Flavopiridol and Vorinostat in Treating
Patients with
Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia
|
| 1108. |
Individualized Drug Treatment Selection Process for Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery
|
| 1109. |
Androgen Suppression Alone or Combined With Zoledronate, Docetaxel, Prednisolone, and/or Celecoxib in Treating Patients With Locally Advanced or Metastatic Prostate Cancer
|
| 1110. |
Positron Emission Tomography Using Fluorothymidine F 18 in Finding Recurrent Disease in Patients With Gliomas
|
| 1111. |
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
|
| 1112. |
Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors
|
| 1113. |
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia That Did Not Respond to Fludarabine (Closed to Entry as of 10/2006), Chronic Lymphocytic Leukemia With Autoimmune Hemolytic Anemia, or Richter Transformation
|
| 1114. |
3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
|
| 1115. |
MRI-Guided Radiation Therapy in Treating Patients With Prostate Cancer
|
| 1116. |
3-AP and Radiation Therapy in Treating Patients With Stage III Pancreatic Cancer That Cannot Be Removed By Surgery
|
| 1117. |
Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
|
| 1118. |
Bendamustine and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
|
| 1119. |
Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia
|
| 1120. |
Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia
|
| 1121. |
Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia
|
| 1122. |
Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia
|
| 1123. |
Docetaxel and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Has Been Completely Removed By Surgery
|
| 1124. |
Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer
|
| 1125. |
Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer
|
| 1126. |
Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
|
| 1127. |
|
